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Abstract
Background: α-Synuclein (aSyn) aggregation is thought to play a central role in neurodegenerative disorders
termed synucleinopathies, including Parkinson’s disease (PD). Mouse aSyn contains a threonine residue at position
53 that mimics the human familial PD substitution A53T, yet in contrast to A53T patients, mice show no evidence
of aSyn neuropathology even after aging. Here, we studied the neurotoxicity of human A53T, mouse aSyn, and
various human-mouse chimeras in cellular and in vivo models, as well as their biochemical properties relevant to
aSyn pathobiology.
Methods: Primary midbrain cultures transduced with aSyn-encoding adenoviruses were analyzed
immunocytochemically to determine relative dopaminergic neuron viability. Brain sections prepared from rats
injected intranigrally with aSyn-encoding adeno-associated viruses were analyzed immunohistochemically to
determine nigral dopaminergic neuron viability and striatal dopaminergic terminal density. Recombinant aSyn
variants were characterized in terms of fibrillization rates by measuring thioflavin T fluorescence, fibril morphologies
via electron microscopy and atomic force microscopy, and protein-lipid interactions by monitoring membrane-
induced aSyn aggregation and aSyn-mediated vesicle disruption. Statistical tests consisted of ANOVA followed by
Tukey’s multiple comparisons post hoc test and the Kruskal-Wallis test followed by a Dunn’s multiple comparisons
test or a two-tailed Mann-Whitney test.
Results: Mouse aSyn was less neurotoxic than human aSyn A53T in cell culture and in rat midbrain, and data
obtained for the chimeric variants indicated that the human-to-mouse substitutions D121G and N122S were at least
partially responsible for this decrease in neurotoxicity. Human aSyn A53T and a chimeric variant with the human
residues D and N at positions 121 and 122 (respectively) showed a greater propensity to undergo membrane-
induced aggregation and to elicit vesicle disruption. Differences in neurotoxicity among the human, mouse, and
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chimeric aSyn variants correlated weakly with differences in fibrillization rate or fibril morphology.
Conclusions: Mouse aSyn is less neurotoxic than the human A53T variant as a result of inhibitory effects of two C-
terminal amino acid substitutions on membrane-induced aSyn aggregation and aSyn-mediated vesicle
permeabilization. Our findings highlight the importance of membrane-induced self-assembly in aSyn neurotoxicity
and suggest that inhibiting this process by targeting the C-terminal domain could slow neurodegeneration in PD
and other synucleinopathy disorders.
Keywords: Adeno-associated virus, Aggregation, Alpha-synuclein, Amyloid, Fibril, Membrane, Neurodegeneration,
Parkinson’s disease, Phospholipid, Synucleinopathy
Background
Parkinson’s disease (PD) is a common progressive neu-
rodegenerative disorder characterized clinically by motor
symptoms attributed to a loss of dopaminergic neurons
in the substantia nigra (SN). At post-mortem examin-
ation neurons in various brain regions of PD patients
present with cytosolic inclusions named Lewy bodies
that contain amyloid-like fibrils of the presynaptic pro-
tein α-synuclein (aSyn) [1]. A number of patients with
familial forms of PD have been found to harbor muta-
tions in the SNCA gene, including point mutations en-
coding the substitutions A30P, E46K, H50Q, G51D,
A53E, and A53T and gene multiplications [2]. Genetic
and neuropathological findings in humans and data from
animal model studies suggest that aSyn self-assembly
plays a central role in the pathogenesis of PD and other
neurodegenerative disorders involving an accumulation
of aSyn aggregates in the brain, collectively referred to
as synucleinopathies [3]. A detailed understanding of
molecular mechanisms by which aSyn forms neurotoxic
aggregates is critical for developing therapies aimed at
slowing neurodegeneration in the brains of patients with
PD and other synucleinopathy disorders.
aSyn has been reported to adopt a natively unfolded,
monomeric structure in solution [4] and to exist as a
compact disordered monomer in mammalian cells [5],
although additional evidence suggests that it can also
exist as an oligomer in the cytosol [6]. The protein is
typically expressed as a 14.4 kDa polypeptide and con-
sists of 3 domains. The N-terminal domain spanning
residues 1–67 contains five conserved, lysine-rich re-
peats. The central region spanning residues 61–95 con-
tains a sixth lysine-rich repeat and is highly
hydrophobic. A key feature of this region is the presence
of a segment spanning residues 71–82 that is required
for aSyn aggregation [7]. The C-terminal region span-
ning residues 96–140 is enriched with proline and acidic
residues and is thought to regulate aSyn aggregation
through auto-inhibitory long-range interactions [8, 9],
with electrostatic interactions mediated by the acidic
residues playing a major role in increasing the fibrilliza-
tion lag time [10]. aSyn binds to anionic phospholipid
vesicles by forming an amphipathic α-helix with varying
lengths, including a short N-terminal helix spanning res-
idues ~ 1–25 and a longer helix spanning residues ~ 1–
97 encompassing both the N-terminal and central
hydrophobic domains [11, 12]. Although membrane
binding apparently plays an important role in the normal
function of aSyn related to regulation of synaptic vesicle
trafficking [12, 13], the protein has also been shown to
undergo accelerated aggregation when incubated in the
presence of phospholipid vesicles at high protein:lipid
ratios [14–16]. aSyn aggregation at the membrane sur-
face is likely stimulated by the exposure of hydrophobic
residues as the membrane-bound protein shifts from the
long-helix form to the short-helix form [11, 16], and by
the fact that molecular interactions needed for aSyn self-
assembly likely occur with a higher probability on the
two dimensional surface of the lipid bilayer than in solu-
tion [17, 18]. Evidence from our laboratory suggests that
membrane-induced aSyn aggregation plays a key role in
neurotoxicity [16], potentially via a mechanism involving
membrane permeabilization [19–22].
An interesting observation regarding aSyn biology is
the fact that mouse aSyn (m-aSyn) naturally contains
a threonine residue at position 53 and is thus identi-
cal to the human familial PD mutant A53T (h-aSyn
A53T) at this site [23]. This observation raises the
question of why h-aSyn A53T triggers accelerated
neurodegeneration in the brains of familial PD pa-
tients, whereas even aged mice show no evidence of
neurodegeneration or the presence of Lewy bodies
[24]. This paradox is particularly striking given that
recombinant m-aSyn forms amyloid-like fibrils more
rapidly than h-aSyn WT or h-aSyn A53T [25, 26], ap-
parently as a result of the disruption of long-range in-
teractions involving the C-terminal region and the N-
terminal and central hydrophobic domains [27]. In
fact, however, m-aSyn differs from h-aSyn-A53T by
six mismatches, one in the central hydrophobic do-
main (S87N) and five in the C-terminal region
(L100M, N103G, A107Y, D121G and N122S) (Fig. 1a),
and each of these could contribute to the apparent
difference in neurotoxicity between the two variants.
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The goal of this study was to investigate the impact of
the mismatches between m-aSyn and h-aSyn A53T on
aSyn neurotoxicity. Previously it was reported that rat
aSyn (which differs from the mouse protein by a single
G-to-S mismatch at position 121) failed to trigger neur-
onal cell death when expressed from a lentiviral vector
infused in rat SN, in contrast to h-aSyn WT and h-aSyn
A53T [28]. Similarly, we found that rat aSyn had a re-
duced ability to trigger nigral dopaminergic cell death
compared to h-aSyn A53T in the rAAV-mediated over-
expression model in the rat [29]. Based on the close se-
quence similarity between mouse and rat aSyn, we
hypothesized that the mouse protein is less neurotoxic
than h-aSyn A53T, potentially because the toxic conse-
quences of having a threonine residue at position 53 are
alleviated by mismatch residues elsewhere in the murine
sequence. To address this hypothesis, we compared h-
aSyn A53T, m-aSyn, and various human-mouse chimeras
in terms of their ability to elicit neurodegeneration in
cellular and animal models relevant to PD and other synu-
cleinopathy disorders. The human and mouse proteins
and a subset of chimeras were further examined for their
ability to form amyloid-like fibrils in the absence of mem-
branes, undergo membrane-induced aSyn aggregation,
and trigger membrane permeabilization.
Methods
Materials
Unless otherwise stated all chemicals were purchased
from Sigma-Aldrich (St. Louis, MO or Stockholm,
Sweden). DMEM, FBS, penicillin-streptomycin, Lipofec-
tamine 2000, Optimem, Trypsin-EDTA, ProLong Gold
Antifade Reagent with DAPI, Proteinase K (25530–049),
and the Virapower Adenoviral Expression System were
obtained from Invitrogen (Carlsbad, CA). Plus slides
(J3800AMNZ), Coomassie Brilliant Blue, and the
Immobilon-FL PVDF membrane were purchased from
Fig. 1 Human and mouse aSyn have seven sequence mismatches. a Sequence alignment of human and mouse aSyn variants showing
mismatches at positions 53, 87, 100, 103, 107, 121, and 122. Also highlighted are the positions of familial PD substitutions and known
serine and C-terminal tyrosine phosphorylation sites. b Schematic representation of human, mouse, and chimeric aSyn variants examined
in this study
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Thermo Fisher Scientific (Rockford, IL). The QuickTiter
Adenovirus Titer Elisa kit was purchased from Cell Bio-
labs (San Diego, CA). Antisedan, Temgesic, and the Fen-
tanyl/Dormitor mixture were obtained from
Apoteksbolaget, (Stockholm, Sweden). The Vectastain
ABC kit was purchased from Vector Laboratories, Inc.
(Burlingame, CA), and 3,3′-diaminobenzidine (DAB
Safe) was obtained from Saveen Werner (Limhamnsvä-
gen, Sweden). Isopropyl β-D-1-thiogalactopyranoside
and ampicillin were purchased from Gold Biotechnology
(St. Louis, MO). L-α-phosphatidylcholine (egg PC), L-α-
phosphatidylglycerol (egg PG), and phospholipid extru-
sion membranes were purchased from Avanti Polar
Lipids (Alabaster, AL). Iodixanol and the enhanced che-
mifluorescence (ECF) substrate were obtained from GE
Life Sciences (Pittsburgh, PA). 100 kDa spin filters and
10 kDa concentration filters were obtained from Milli-
pore (Billerica, MA or Solna, Sweden).
Antibodies
The following antibodies were used in these studies:
Primary cell culture – chicken anti-microtubule associ-
ated protein 2 (MAP2) (CPCA-MAP2, RRI-
D:AB_2138173, EnCor Biotechnology, Gainesville, FL);
rabbit anti-tyrosine hydroxylase (TH) (AB152, RRI-
D:AB_390204, Millipore, Bellerica, MA); anti-rabbit
IgG-Alexa Fluor 488 (R37116, RRID:AB_2556544) and
anti-chicken IgG-Alexa Fluor 594 (A11042, RRI-
D:AB_142803) (Thermo Fisher Scientific, Rockford, IL).
In vivo experiments – human-specific syn211 (36–008,
RRID:AB_310817, Millipore, Germany); mouse anti-
aSyn, clone 42 (Syn-1) (610,787, RRID:AB_398108, BD
Biosciences, UK); rabbit anti-TH (P40101–0, RRI-
D:AB_461064, Pel-freeze, USA); rabbit anti-VMAT2
(ab81855, RRID:AB_2188123, Abcam, UK or 20,042,
RRID:AB_10013884, Immunostar, USA); mouse anti-
HuC/HuD, clone 16A11 (A21271, RRID:AB_221448,
Thermo Scientific, USA); biotinylated secondary anti-
bodies (Vector Laboratories Inc., USA).
Western blotting – mouse anti-aSyn, clone 42 (Syn-1)
(610,787, RRID:AB_398108, BD Biosciences, San Jose,
CA); AP-linked anti-mouse IgG (7056, RRI-
D:AB_330921) (Cell Signaling Technology, Danvers,
MA).
Preparation of bacterial expression constructs
Bacterial expression constructs encoding h-aSyn WT
(pT7–7-h-aSyn), h-aSyn A53T (pT7–7-h-aSyn-A53T),
and m-aSyn (pT7–7-m-aSyn) were described previously
[26]. A construct encoding h-aSyn Chimera was gener-
ated by replacing the BamHI-HindIII fragment of pT7–
7-h-aSyn-A53T (encompassing base pairs 354–423 of
the h-aSyn A53T cDNA) with the equivalent fragment
from pT7–7-m-aSyn. A construct encoding m-aSyn
Chimera was generated by replacing the BamHI-HindIII
fragment of pT7–7-m-aSyn (encompassing base pairs
354–423 of the m-aSyn cDNA) with the equivalent frag-
ment from pT7–7-h-aSyn-A53T. pT7–7 constructs en-
coding A53T/D121G, A53T/N122S, A53T/S87N, h-aSyn
Chimera S87N, m-aSyn N87S, and m-aSyn Chimera
N87S were generated via site-directed mutagenesis using
the QuikChange method (Stratagene). The sequence of
the DNA insert in each bacterial expression construct
was verified using an Applied Biosystems (ABI3700)
DNA sequencer (Purdue Genomics Core Facility).
Adenoviral vector design and virus production
Adenoviral constructs encoding h-aSyn WT and h-aSyn
A53T were described previously [16, 30]. cDNAs encod-
ing h-aSyn Chimera, A53T/D121G, A53T/N122S,
A53T/S87N, and h-aSyn Chimera S87N (obtained using
the pT7–7 constructs outlined above as PCR templates)
were subcloned as KpnI-XhoI fragments into the entry
vector pENTR1A. cDNAs encoding m-aSyn, m-aSyn
Chimera, and m-aSyn Chimera N87S were subcloned as
SalI-XhoI fragments into pENTR1A. Inserts from the
pENTR1A constructs were then transferred into the
pAd/CMV/V5 adenoviral expression vector via recom-
bination using Gateway LR Clonase. The sequence of
the DNA insert in each adenoviral construct was verified
using an Applied Biosystems (ABI3700) DNA sequencer
(Purdue Genomics Core Facility). Adenoviral constructs
were packaged into virus via lipid-mediated transient
transfection of the HEK 293A packaging cell line. Puri-
fied adenoviral particles were titered using the QuickTi-
ter Adenovirus Titer Elisa kit.
AAV vector design and virus production
Adeno-associated viral vectors of serotype 5 (AAV5)
were comprised of a genome cassette flanked by inverted
terminal repeats (ITR2). The cassette contained a
chicken beta-actin promoter in combination with a
CMV enhancer element (CBA) leading to expression of
one of the four different transgenes. Genes were PCR-
amplified with the plasmids pENTR1A h-aSyn A53T,
pENTR1A h-aSyn Chimera, pENTR1A m-aSyn, and
pENTR1A m-aSyn Chimera as templates and subcloned
as HindIII-SpeI fragments in the pTR-UF20 plasmid.
The validity of the constructs was confirmed by restric-
tion analysis and Sanger sequencing. Downstream of
each cDNA insert was an h-SV40 polyA transcription
termination sequence. HEK293 cells were co-transfected
at a confluency of 70–80% using the calcium-phosphate
precipitation method. Plasmids used here encode essen-
tial adenoviral packaging and AAV5 capsid genes as pre-
viously described [31]. Three days after transfection,
cells were harvested in PBS and lysed by performing
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three freeze-thaw cycles in a dry ice/ethanol bath. The
lysate was then treated with benzonase and purified
using a discontinuous iodixanol gradient followed by
Sepharose Q column chromatography [32]. Vectors were
concentrated using a 100 kDa molecular weight cut-off
column, and titers of the stock solution were determined
by qPCR using primers and probes targeting the ITR se-
quence. Before being used in an experiment, vectors
were diluted in PBS, pH 7.4 and re-titered, yielding the
values reported in the Results and in Fig. 3.
Preparation and treatment of primary mesencephalic
cultures
Primary midbrain cultures were prepared via dissection
of day 17 embryos obtained from pregnant Sprague-
Dawley rats (Harlan, Indianapolis, IN, USA) as described
[16, 30]. The cells were plated on poly-L-lysine-treated
48-well plates at a density of 163,500 cells per well. Five
days after plating, the cells were treated with cytosine
arabinofuranoside (AraC) (20 μM, 48 h) to inhibit the
growth of glial cells. At this stage (i.e., 7 days in vitro
(DIV)), the neurons appeared differentiated with ex-
tended processes. The cultures were transduced with ad-
enoviruses encoding the aSyn variants for 72 h at a
multiplicity of infection (MOI) ranging from 7 to 15 to
ensure equal expression levels as determined via West-
ern blotting. After incubation for an additional 24 h in
fresh medium without virus, the cells were fixed in 4%
(w/v) PFA in PBS (pH 7.4) and permeabilized and
blocked simultaneously for 30 min with PBS containing
1% (w/v) BSA, 10% (v/v) FBS, and 0.3% (v/v) Triton X-
100. The cells were then washed in PBS and incubated
with chicken anti-MAP2 (1:2000) and rabbit anti-TH (1:
500) for 24 h at 4 °C. After an additional wash in PBS,
the cultures were incubated with AlexaFluor 594-
conjugated goat anti-chicken and AlexaFluor 488-
conjugated goat anti-rabbit secondary antibodies (1:
1000) for 1 h at 22 °C. ProLong Gold Antifade Reagent
with DAPI was applied to each well, and a coverslip was
added.
Measurement of neuronal viability in midbrain cultures
Relative dopaminergic cell viability was evaluated as de-
scribed [16, 30]. MAP2+ and TH+ cells were counted in
a blinded manner in at least 10 randomly chosen obser-
vational fields (approximately 500–1000 neurons total)
for each experimental condition using a Nikon TE2000-
U inverted fluorescence microscope (Nikon Instruments,
Melville, NY) equipped with a 20x objective. The data
are expressed as the percentage of MAP2+ neurons that
are also TH+ to correct for variation in cell density. Each
experiment was repeated a minimum of 3 times with
cultures isolated from different pregnant rats.
Animals for in vivo experiments
Young adult Sprague-Dawley rats received from Charles
River (Kisslegg, Germany) were housed on a 12 h light-
dark cycle with ad libitum access to water and food.
Stereotaxic surgery
Rats were anesthetized via i.p. injection of a 20:1 mixture
of Fentanyl and Dormitor (6 mL/kg). After placing each
animal into a stereotaxic frame (Stoelting, Wood Dale,
USA), the SN was targeted unilaterally using the follow-
ing coordinates: anteroposterior (AP), − 5.0 mm; medio-
lateral (ML), − 2.0 mm from bregma; and dorsoventral
(DV), − 7.2 mm from the dura. The tooth bar was
adjusted to − 2.3 mm. A pulled glass capillary (about 60–
80 μm in diameter) was attached to a 5 μL Hamilton syr-
inge equipped with a 22 s gauge needle and used to
deliver 2 μL of rAAV5 vector solution at a pulsed injec-
tion of 0.1 μL every 15 s. After delivery of the vector, the
capillary was left in place for 5 min, retracted 0.1 mm,
and after 1 min it was slowly removed from the brain.
After closing the wound with clips, Antisedan and Tem-
gesic were administered s.c. as an analgesic treatment
and to reverse the anesthesia.
Histology
An overdose of sodium pentobarbital was used to kill
rats 8 weeks after vector delivery. Animals were perfused
via the ascending aorta first with 50mL of 0.9% (w/v)
NaCl followed by 250 mL of ice-cold 4% (w/v) PFA in
0.1M phosphate buffer, pH 7.4, for 5 min. Brains were
taken out and post-fixed in 4% (w/v) PFA for 24 h and
then incubated in 25% (w/v) sucrose for cryoprotection.
Brains were cut on a microtome (Microm HM450,
Thermo Scientific, USA) in 35 μm-thick coronal sections
and placed into antifreeze solution (0.5M phosphate
buffer, 30% (v/v) glycerol, 30% (v/v) ethylene glycol) at
− 20 °C for long term storage until further processed.
Immunohistochemical staining was performed on
free-floating brain sections. Specimens were rinsed
with Tris-buffered saline (TBS) buffer (5 mM Tris-
HCl, 15 mM NaCl, pH 7.6). Only TH staining re-
quired an antigen retrieval step carried out for 30 min
at 80 °C using Tris/EDTA buffer (10 mM Tris-HCl, 1
mM EDTA, pH 9.1). This step was terminated by re-
peated washes in TBS at 22 °C. Endogenous peroxid-
ase activity was quenched using a solution of 3% (v/v)
H2O2 and 10% (v/v) methanol in TBS buffer for 30
min, and the reaction was stopped by washing sec-
tions 3 times with TBS. To block unspecific binding
sites, sections were incubated for 30 min in 0.05% (v/
v) Triton X-100 in TBS buffer (TBS-T) containing 5%
(v/v) normal serum from the same species as that in
which the secondary antibody was raised. The pri-
mary antibodies were then applied in 1% (w/v) BSA
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in TBS-T overnight at 22 °C: human-specific syn211
at 1:100,000; Syn-1 at 1:10,000; TH at 1:5000;
VMAT2 ab81855 at 1:4000, or 20,042 at 1:10,000;
HuC/HuD 1:200. The next day sections were washed
in TBS-T, and the appropriate biotinylated secondary
antibody (1:200) was applied in 1% (w/v) BSA in
TBS-T for 1 h. Specimens were rinsed once more
with TBS-T and further incubated in a solution con-
taining avidin-biotin-peroxidase complexes (Vectastain
ABC kit, Vector Laboratories Inc., USA) for 1 h.
Staining was visualized using 3,3′-diaminobenzidine
(DAB Safe) and 0.01% (v/v) H2O2. Sections were then
mounted on chromatin-gelatin coated glass slides,
dehydrated in increasing alcohol solutions, cleared
with xylene, and applied to coverslips using DPX
(06522, Sigma-Aldrich, Sweden).
For cresyl violet staining, sections were mounted on
chromatin-gelatin coated glass slides and dried over-
night. Sections were then hydrated in decreasing alco-
hol solutions and stained for 30 s in 0.5% (w/v) cresyl
violet + 0.1% (v/v) acetic acid. After rinsing specimens
with H2O, sections were dehydrated in increasing al-
cohol solutions, cleared in xylene, and coverslipped
using DPX.
To visualize insoluble aggregates, sections were treated
with Proteinase K. For this purpose, specimens were first
rinsed with potassium-containing phosphate-buffered sa-
line (KPBS) and then heat-treated at 80 °C for 30 min in
KPBS. Sections were then quenched using 3% (v/v)
H2O2 and 10% (v/v) methanol in KPBS for 30 min. After
mounting sections on plus slides, the sections were incu-
bated in a KPBS solution containing 10 μg/mL Protein-
ase K for either 5 or 45 min. The same staining protocol
was applied as described above using the aSyn-specific
primary antibody Syn-1 at 1:1000.
Stereological analysis
In order to estimate surviving TH+ nigral neurons, an
unbiased stereological quantification using the optical
fractionator method [33, 34] was applied. The imple-
mentation of a random starting position and systematic
sampling was done using the Visiopharm VIS software
(version 4.5.5.433 Visiopharm A/S, Denmark) and a
Nikon Eclipse 80i light microscope fitted with an xy mo-
torized stage, a motorized z-axis (Prior, UK), and a
microcator (Heidenheim, Germany). Through the
rostro-caudal axis of the SN, every 6th section was
stained for TH. Regions of interest were outlined with a
4x objective, and counting was executed using a 60x oil-
immersion objective with a numerical aperture of 1.4.
Counting parameters were set to reach at least 100 cell
counts per hemisphere. Estimation of the total number
of TH+ cells was performed by a single blinded investi-
gator. The coefficient of error due to the sampling was
calculated based on Gundersen and Jensen [35], and
values lower than 0.1 were considered acceptable. The
contralateral uninjected side of each animal served as an
internal control, and values were expressed as a percent-
age of cell counts on the injected side relative to the in-
tact side (mean ± SEM).
Densitometry
The optical density of TH+ and VMAT2+ fibers was
measured on digital images of coronal striatal sections
using the Zeiss microscope (Axio Zoom.V16, Zeiss,
Germany). The striatum of every 24th section in the
rostro-caudal axis – in total 6 sections per brain – was
outlined using ImageJ, and optical density readings were
corrected for non-specific background using density
measurements from the corpus callosum of each animal.
Data consisting of means ± SEM from all brains are
expressed as a percentage of contralateral side values.
Protein purification
Recombinant aSyn variants were purified from BL21
(DE3) cells transformed with pT7–7 constructs as de-
scribed [16]. The final purity of each protein was found
to be > 98% as determined by SDS-PAGE with Coomas-
sie Blue staining.
aSyn fibrillization
Lyophilized aSyn was dissolved in PBS (pH 7.4) with
0.02% [v/v] NaN3, and the solution was filtered by suc-
cessive centrifugation steps through a 0.22 μm spin filter
and a 100 kDa centrifugal filter to isolate monomeric
protein. The stock solution was dialyzed against the
same buffer (24 h at 4 °C) to remove excess salt. Fibrilli-
zation solutions of aSyn were prepared by diluting the
appropriate stock solutions of dialyzed protein with buf-
fer to a final concentration of 35 μM in the wells of a
96-well plate. To determine the extent of aSyn fibrilliza-
tion, thioflavin T (ThioT, final concentration, 20 μM)
was added to the fibrillization solutions, which were in-
cubated at 37 °C with shaking at the ‘normal’ setting in a
Spectra Fluor Plus or Genios plate reader (Tecan,
Upsala, Sweden). ThioT fluorescence was measured with
excitation at 440 nm and emission at 490 nm. Mean
ThioT fluorescence data determined from 3 or 4 tech-
nical replicates (defined here as samples treated identi-






where Ft is the ThioT fluorescence emission intensity at
time t, and Fmin and Fmax are the minimum and
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maximum fluorescence intensities during the incubation,
respectively.
Lipid vesicle preparation
Small unilamellar vesicles (SUVs) (diameter = 50 nm)
were prepared as described [16]. We opted to examine
SUVs composed of egg PG and egg PC (1:1 mol/mol)
because they contain anionic lipids necessary for aSyn
membrane interactions [12] and this lipid composition is
compatible with producing stable 50 nm vesicles [16].
Egg PG and egg PC suspended in chloroform were
mixed in a round bottom flask. The chloroform was
evaporated under a nitrogen stream and further dried
under vacuum for 1 h. Dried lipids were suspended in
PBS, and 50 nm SUVs were prepared by extruding the
suspension through a Whatman membrane. The size of
the vesicles was confirmed by dynamic light scattering.
Lipid vesicles were stored at 4 °C prior to use.
Circular dichroism
Far-UV CD measurements were performed as described
[16] using a Chirascan SC spectrometer (Applied Photo-
physics, Leatherhead, UK). Solutions of recombinant
aSyn (5 μM in 20 mM KPi, pH 7.4) in the absence or
presence of SUVs (protein-to-lipid ratio, 1:50 to 1:1600,
mol/mol) were analyzed in a 1 mm quartz cuvette at
25 °C. The ellipticity at 222 nm was recorded and back-
ground corrected to eliminate scattering signals arising
from the SUVs. The mean residue molar ellipticity at
222 nm ([θ]MR, 222) was calculated using the following
equation:
θ½ MR;222 ¼ θ222=10Cnl ð2Þ
where θ222 is the observed (background corrected) ellip-
ticity at 222 nm in millidegrees, C is the protein concen-
tration in M, n is the number of amino acid residues in
the protein, and l is the path length of the cuvette in cm.
Binding curves were generated by plotting [θ]MR, 222 ver-
sus the lipid concentration. Curves were analyzed by fit-
ting to the following equation:
R ¼ R0− R0−R f
 
Kd þ C þ L=N−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi






where R is the measured [θ]MR, 222 at a given lipid con-
centration, R0 is [θ]MR, 222 in the absence of lipid, Rf is
[θ]MR, 222 in the presence of saturating lipid, L is the
total lipid concentration, C is the total protein concen-
tration, Kd is the apparent macroscopic dissociation
equilibrium constant, and N is the binding stoichiometry
(lipids/protein) [16, 36].
To determine the maximal helical content of each










θcoil ¼ 640−45t ð6Þ
where H is the maximal % helicity, θ is [θ]MR, 222 in the
presence of saturating lipid (Rf in Eq. 3), θα is the [θ]MR,
222 value of an idealized α-helical peptide, θcoil is the
[θ]MR, 222 value of an idealized random coil peptide, n is
the number of amino acid residues in the protein (=
140), and t is the temperature (25 °C) [16, 37, 38].
Lipid flotation assay
Lipid flotation analyses were carried out as described
[16, 22]. Lyophilized aSyn was resuspended in PBS with
0.02% (w/v) NaN3, and the solution was dialyzed against
the same buffer to remove salts and filtered by succes-
sive centrifugation steps through a 0.22 μm spin filter
and a 100 kDa centrifugal filter to isolate monomeric
protein. aSyn (40 μM) was incubated with PG:PC SUVs
(protein-to-lipid ratio, 1:20 mol/mol) at 37 °C for 72 h in
a total volume of 60 μL. After incubation, the sample
was mixed with 4 mL of 30% (v/v) iodixanol solution
and overlaid with 7.0 mL of 25% (v/v) iodixanol and
350 μL of 5% (v/v) iodixanol in a polyalomar tube (Beck-
man, Miami, FL). All of the above iodixanol solutions
were prepared in lipid flotation buffer (10 mM HEPES,
pH 7.4, 150 mM NaCl). The samples were spun at 200,
000 x g in a Beckman SW 41 Ti rotor for 4 h. The mem-
brane fraction was carefully collected from the 5% iodix-
anol fraction at the top of the gradient, concentrated
using a 10 kDa spin filter, and analyzed via Western
blotting using a primary antibody specific for aSyn (Syn-
1) (1:1500) [16, 22]. In general, we found that the rate of
aSyn aggregation increased in the presence of SUVs that
had been stored for ~ 2–4 weeks at 4 °C [16].
Synthetic vesicle disruption assay
Calcein-loaded egg PG:PC SUVs were prepared as de-
scribed [39] with some modifications. A solution of cal-
cein (170 mM) was prepared in H2O using NaOH to
adjust the pH to 7.4. The final osmolality was 280
mOsm/kg. The calcein solution was used to resuspend
dried egg PG:PC lipids, and the suspension was extruded
through a Whatman membrane to generate 50 nm
SUVs. Calcein-containing vesicles were isolated from
free calcein via gel filtration through a Sephadex G-50
column pre-equilibrated with PBS, pH 7.4, 0.02% (w/v)
NaN3 (280 mOsm/kg). Fractions containing isolated ves-
icles were pooled and stored at 4 °C until use. Calcein-
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loaded vesicles were found to be very stable, with no
spontaneous dye leakage observed over several weeks.
For membrane disruption experiments, monomeric
aSyn variants were isolated as described above (see ‘Lipid
flotation assay’). Each aSyn variant (40 μM) was incu-
bated with calcein-loaded PG:PC SUVs (protein-to-lipid
ratio, 1:20 mol/mol) at 37 °C in a total volume of 40 μL.
At each time point, 3 μL of the reaction mixture was di-
luted into 180 μL of PBS, and the diluted samples were
analyzed with a Fluoromax-3 spectrofluorometer (Hor-
iba Scientific, Edison, New Jersey) (excitation wave-
length, 485 nm; emission wavelengths, 505–530 nm; slit
width, 1 nm). To determine the maximum dye release,
vesicles were lysed by adding 5 μL of 1% (v/v) Triton X-






where It is the fluorescence emission intensity at time t,
I0 is the intensity at time 0, and Imax is the maximal in-
tensity determined after detergent lysis of the vesicles
(intensity values were determined at 515 nm).
Atomic force microscopy analysis of aSyn amyloid-like
fibrils
A mica surface functionalized with 1-(3-aminopropyl)
silatrane (APS) was used to image aSyn amyloid-like fi-
brils by atomic force microscopy (AFM) [18, 40–42].
APS-mica was prepared by incubating freshly cleaved
mica in a solution of APS (167 μM) for 30 min and then
rinsed with deionized water and dried with an argon
stream. A suspension of aSyn fibrils (10 μL, prepared as
described above under ‘aSyn fibrillization’ with an incu-
bation time of ~ 100 h and diluted 1/20 in deionized
water) was deposited onto the APS-mica surface, and
the sample was incubated for 2 min, rinsed with deion-
ized water, and dried under an argon stream. The sam-
ple was imaged with an AFM Nanoscope VIII system
(Bruker, Santa Barbara, CA) using MSNL probes (Canti-
lever F with spring constant 0.6 N/m), operating in air in
peak force mode. Images were acquired over a few ran-
domly selected locations. Images were analyzed using
Gwyddion and FemtoScan online software (Advanced
Technologies Center, Moscow, Russia) [43, 44].
TEM analysis of aSyn amyloid-like fibrils
The morphology of aSyn amyloid-like fibrils (prepared
as described above under ‘aSyn fibrillization’ with an in-
cubation time of ~ 100 h) was analyzed by negative stain
biological TEM [45]. For biological sample preparation
by negative staining, which is a sample preparation tech-
nique that imparts the necessary contrast for viewing
during biological TEM imaging, 3 μL of aSyn sample so-
lution (35 μM) was pipetted on a discharged carbon-
coated copper TEM grid substrate. Subsequently, the
sample was washed with deionized water carefully with-
out letting it dry and stained with a 1% (w/v) phospho-
tungstic acid solution (3 μL), which was left in contact
with the protein on the grid for 1 min. The excess solu-
tion was then removed by blotting with filter paper, and
the sample was imaged using an FEI Tecnai G2 20
Transmission Electron Microscope operating at 200 KV.
Sample size estimation
Samples sizes for studies of primary neuron viability,
membrane-induced aSyn aggregation, and aSyn-mediated
membrane permeabilization were estimated via power
analysis based on our previous studies [16, 22]. Power ana-
lyses were designed to determine the number of biological
replicates required to detect a ~ 20% or ~ 30% difference
from control, with α = 0.05 (type I error) and power = 0.80
(statistical power). Biological replicates are defined here as
samples treated identically in independent experiments
carried out on different days. For in vivo experiments,
sample sizes were estimated based on previous data col-
lected by our group and others for the A53T variant.
Statistical analysis
Statistical analyses were carried out using GraphPad
Prism 6.0 (La Jolla, CA). Primary neuron viability data,
in vivo stereology and densitometry data, densitometry
data from Western blots, and calcein dye release data
were analyzed via ANOVA followed by Tukey’s multiple
comparisons post hoc test for normally distributed mea-
surements. In analyzing percentage dye release data and
percentage cell viability data by ANOVA, square root
transformations were carried out to conform to ANOVA
assumptions. The Kruskal-Wallis test followed by a
Dunn’s multiple comparisons test or a two-tailed Mann-
Whitney test was used as a non-parametric test. Differ-
ences were considered significant for p < 0.05. Unless
otherwise stated, values of n indicated in the Figure Leg-
ends refer to the number of independent biological
replicates.
Results
Neurotoxicity of aSyn variants in primary midbrain
culture
In the first part of our study, we used a primary mesen-
cephalic cell culture model to examine the effects of
amino acid variations between m-aSyn and h-aSyn A53T
on aSyn neurotoxicity. In addition to h-aSyn A53T and
m-aSyn, two chimeric variants were analyzed: (i) h-aSyn
Chimera, consisting of h-aSyn with the human-to-mouse
substitutions A53T, D121G, and N122S; and (ii) m-aSyn
Chimera, consisting of m-aSyn with the mouse-to-
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human substitutions G121D and S122N (Fig. 1b). We
chose to examine the effects of substitutions at positions
121 and 122 based on data showing that post-
translational modifications near these residues, including
C-terminal truncation and Y125 phosphorylation, modu-
late the protein’s aggregation propensity and neurotox-
icity [46–50].
Primary midbrain cultures were processed as un-
treated control or transduced with adenovirus encoding
each of the aSyn variants at MOIs that were adjusted to
ensure equal expression of the different variants. We
have previously shown that the adenoviral transduction
efficiency is > 90% for dopaminergic and non-
dopaminergic neurons [16]. The cells were fixed and
stained for MAP2, a general neuronal marker, and TH, a
marker of dopaminergic neurons. Relative dopaminergic
cell viability was evaluated by determining the percent-
age of MAP2+ neurons that were also TH+. We found a
significant reduction in the percentage of TH+ neurons
in cultures transduced with h-aSyn A53T virus com-
pared to untreated cultures or cultures expressing m-
aSyn (Fig. 2a, b). Cultures expressing m-aSyn Chimera
exhibited a decrease in relative TH+ cell viability, similar
to A53T-expressing cultures (Fig. 2b). In contrast, h-
aSyn Chimera had no impact on dopaminergic cell sur-
vival, similar to m-aSyn (Fig. 2a). In additional experi-
ments we found that cultures expressing A53T/D121G
(but not A53T/N122S) exhibited a significant decrease
in TH+ neuron loss compared to cultures expressing
A53T (Fig. 2c). Together these results suggested that (i)
h-aSyn A53T is more neurotoxic than m-aSyn, and (ii)
the human-to-mouse substitutions D121G and N122S
(and in particular D121G) are at least partially respon-
sible for the decrease in neurotoxicity of m-aSyn com-
pared to h-aSyn A53T.
In an independent set of experiments, we examined
the impact of the mismatch between m-aSyn and h-
aSyn A53T at position 87 (Fig. 1) on aSyn-mediated
dopaminergic cell death. Here our rationale was that
residue 87 is located in the central hydrophobic do-
main, and substitutions and deletions in this region
have been shown to modulate aSyn aggregation and
neurotoxicity [7, 47]. Cultures expressing h-aSyn
A53T/S87N, h-aSyn Chimera S87N, or m-aSyn
Chimera N87S exhibited no difference in relative
dopaminergic cell viability compared to cultures ex-
pressing h-aSyn A53T (Fig. 2d), h-aSyn Chimera (Fig.
2e), or m-aSyn Chimera (Fig. 2f), respectively. From
these results, we inferred that the mismatch between
m-aSyn and h-aSyn A53T at position 87 does not
affect aSyn neurotoxicity.
Taken together, these findings suggest that residues
D121 and N122 are important for the ability of h-aSyn
A53T to elicit dopaminergic cell death. Moreover, we
infer that residues G121 and S122 (but not N87) of m-
aSyn interfere with the expected neurotoxic effect of the
threonine residue at position 53 of the mouse sequence.
Neurotoxicity of aSyn variants in rat nigrostriatal
projection neurons
To further examine the effects of mismatches at posi-
tions 121 and 122 of m-aSyn and h-aSyn A53T on aSyn
neurotoxicity, we characterized h-aSyn A53T, m-aSyn,
h-aSyn Chimera, and m-aSyn Chimera in terms of their
toxicity to nigral dopamine neurons in vivo. rAAV vec-
tors encoding these variants were injected unilaterally
into the rat SN at two different titers, corresponding to a
low-toxicity titer at 1.3E13 gc/mL (n = 4–6 per group)
and a high-toxicity titer at 3.5E14 gc/mL (n = 4–10 per
group). Animals were killed 8 weeks after transduction,
and serial coronal midbrain sections were stained for
histological analysis to assess transgene expression and
the extent of neurodegeneration in the nigral dopamine
neurons. Representative specimens of animals injected
with a high-titer vector are shown in Fig. 3a-y. The aSyn
antibody applied here was used to evaluate transgene ex-
pression and is specific for aSyn but does not distinguish
between human and rodent variants as seen in Fig. 3a,
where endogenous aSyn can be visualized especially in
the axon terminal located in the SN pars reticulata
contralateral to the AAV injection. On the injected side,
transduced cells over-expressing h-aSyn A53T (Fig. 3b),
h-aSyn Chimera (Fig. 3c), m-aSyn (Fig. 3d), or m-aSyn
Chimera (Fig. 3e) were visible in the SN pars compacta.
The human aSyn-specific syn211 antibody resulted in
specific staining in groups expressing h-aSyn A53T or
m-aSyn Chimera, whereas the contralateral side of rat
midbrain sections as well as sections expressing m-aSyn
or h-aSyn Chimera were devoid of any immunoreactivity
(Figure S1). Notably, staining with a pan aSyn antibody,
Syn-1, showed that the overexpression was present in all
groups, suggesting that the affinity of syn211 to the aSyn
variants was dependent on the identity of the residues at
positions 121 and 122 (Figure S1F-J).
Immunohistochemical analyses were carried out to
evaluate the loss of dopaminergic neurons in rat mid-
brain sections stained for TH (Fig. 3f-j) and vesicular
monoamine transporter 2 (VMAT2) (Fig. 3k-o). A clear
loss of TH+ as well as VMAT2+ neurons was seen in all
groups when compared to the uninjected contralateral
side (Fig. 3f and k, respectively). The reduction in cell
numbers was not due to a loss of expression of dopa-
minergic markers, as it was clearly visible also in speci-
mens stained with antibodies against the neuronal
marker proteins Hu (Fig. 3p-t) or with cresyl violet (CV)
(Fig. 3u-y). In order to quantify dopaminergic cell loss in
the SN, we counted TH+ cells in serial sections from
both the low-titer and high-titer vector groups. Results
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obtained for the low-titer group showed no cell death
for any of the aSyn variants and no significant differ-
ences among groups (Fig. 3z). In contrast, in the 3.5E14
gc/mL titer groups, the expression of h-aSyn A53T re-
sulted in a significantly higher percentage of cell death
when compared to the h-aSyn Chimera group (75 ± 4
versus 50 ± 5% cell loss, respectively; Fig. 3aa). Moreover,
the m-aSyn group displayed significantly reduced neuro-
toxicity in TH+ neurons compared to the m-aSyn
Chimera group (56 ± 8 versus 17 ± 3% cell survival,
Fig. 2 Human/mouse mismatches at positions 121 and 122 affect aSyn neurotoxicity in cell culture. Primary midbrain cultures were transduced
with adenovirus encoding human, mouse, and chimeric aSyn variants at MOIs adjusted to ensure equal expression levels. Additional cultures
were untransduced (‘control’). The cells were fixed, stained with antibodies specific for MAP2 and TH, and scored for dopaminergic cell viability.
The data are presented as the mean ± SEM, n = 4 (a, b), n = 5 (c), or n = 3 (d-f). *p < 0.05, **p < 0.01, ***p < 0.001; square root transformation,
one-way ANOVA followed by Tukey’s multiple comparisons post hoc test. The datasets represented by panels a-d and f are partially overlapping
with respect to replicate data obtained for Control, h-asyn A53T, and m-asyn
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respectively). These results suggested a considerable ef-
fect of the human/mouse mismatches at positions 121
and 122 on aSyn-mediated dopaminergic cell death in
rat SN.
To determine whether the significant differences in
dopaminergic cell death observed in the SN were also evi-
dent in the nigrostriatal projections, we evaluated the TH+
and VMAT2+ fiber intensity in the striatum of the high
Fig. 3 Human/mouse mismatches at positions 121 and 122 affect aSyn-mediated dopaminergic cell death in rat midbrain. Rats (4–10 per group)
were injected unilaterally into the SN with vectors encoding h-aSyn A53T, h-aSyn Chimera, m-aSyn, or m-aSyn Chimera at two different titers
(1.3E13 gc/ml or 3.5E14 gc/ml). Eight weeks after surgery, coronal midbrain sections of the high-dose group were stained for aSyn in order to
visualize transgene expression (a-e). Adjacent specimens were stained for TH (f-j), VMAT2 (k-o), Hu (p-t) or cresyl violet (u-y). The first panel in
each row shows a representative image of the contralateral uninjected side (a, f, k, p, u). Counts of TH+ nigral dopaminergic neurons are shown
in z for the lower vector dose and in aa for the higher vector dose. Data are presented as the percentage of intact side cell numbers ± SEM.
**p < 0.01; two-tailed Mann-Whitney U test. Scale bar, 50 μm (panels a-y). See also Figure S1
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titer groups. In serial sections throughout the rostro-
caudal axis of the striatum, we found a reduction in stain-
ing intensity for both TH (Fig. 4a-e, a’-e’) and VMAT2
(Fig. 4f-j, f’-j′) for all groups when compared to contralat-
eral striatal areas. A significant reduction of innervation
density was observed for the m-aSyn Chimera group when
compared to the m-aSyn group for both TH+ (Fig. 4k) and
VMAT2+ projections (Fig. 4l). These observations are in
accordance with dopaminergic cell loss seen in the corre-
sponding SN sections of the same animals. There was a
trend for a difference in the h-aSyn Chimera group when
compared to the h-aSyn A53T group, although this did
not reach significance [TH (p = 0.11); VMAT2 (p = 0.27)].
Aggregate formation by aSyn variants in rat midbrain
To determine whether the aSyn variants differed in
terms of aggregation propensity in rat midbrain, we
treated striatal sections with Proteinase K (PK) to digest
non-aggregated species and reveal digestion-resistant
aSyn assemblies. As a reference for the PK incubation
we chose the endogenous aSyn staining in the CA3 re-
gion of the hippocampus (Figure S2A, F, K), which
would not be affected by nigral transduction. Whereas
untreated striatal sections stained for aSyn showed both
punctate and fiber-like staining (Figure S2B-E), a clear-
ance of digested and therefore non-aggregated aSyn
could already be appreciated after 5 min of PK incuba-
tion (Figure S2F-J). At a later incubation time (45 min)
when endogenous aSyn staining could no longer be de-
tected in the CA3 region (Figure S2K), and therefore all
non-aggregated synuclein would be digested, resistant
aSyn aggregates were detected in striatal sections in all
groups (Figure S2L-O). These results suggested that the
human/mouse mismatches at positions 121 and 122 do
not have a major impact on the ability of aSyn to form
PK-resistant aggregates in the striatal fiber terminals of
dopaminergic neurons.
Effects of human/mouse aSyn mismatches on aSyn
fibrillization rates
The next set of experiments was aimed at determin-
ing the effects of human/mouse aSyn mismatches on
rates of aSyn fibrillization. Based on evidence that m-
aSyn forms amyloid-like fibrils more rapidly than h-
aSyn WT or A53T [25, 26], we hypothesized that a
more rapid conversion of natively unfolded aSyn to
Fig. 4 Mouse-to-human substitutions at positions 121 and 122 enhance the ability of m-aSyn to elicit dopaminergic fiber loss in rat striatum.
Representative striatal rat brain sections stained for TH or VMAT2 (6–10 per group) are shown in panels a-e or f-j, respectively, as low-
magnification images, and in panels a’-e’ or f’-j’, respectively, as corresponding high-magnification images. The imaged sections were from
animals injected with the highest vector dose. The first panel of each row shows a representative image of the contralateral uninjected side (a, a’,
f, f’). Quantified staining intensities of the striatum are displayed in k for TH and l for VMAT2. Data are presented as the percentage of
corresponding contralateral staining intensity ± SEM. *p < 0.05; two-tailed Mann-Whitney U test. Scale bar, 1 mm (panels a-j) or 50 μm (panels a’-
j’). See also Figure S2
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mature, amyloid-like fibrils could lead to a depletion
of toxic oligomers [26, 51, 52]. As a corollary, we rea-
soned that the human-to-mouse substitutions could
stimulate aSyn fibrillization, which in turn could ac-
count for the reduced neurotoxicity of m-aSyn and h-
aSyn Chimera compared to h-aSyn A53T. To address
this hypothesis, we monitored the fibrillization of hu-
man, mouse, and chimeric aSyn variants using a thio-
flavin T fluorescence assay. Consistent with previous
results, we found that m-aSyn and h-aSyn A53T
formed fibrils with a markedly reduced lag time com-
pared to h-aSyn WT, although the decrease in lag
time was more pronounced for the mouse protein
(Fig. 5a). Analysis of the chimeric aSyn variants re-
vealed that h-aSyn Chimera formed fibrils with a lon-
ger lag time compared to h-aSyn A53T, whereas the
rate of fibrillization was only slightly decreased for m-
aSyn Chimera compared to m-aSyn (Fig. 5b).
Secondly, we investigated the effects of the human/
mouse mismatch at position 87 on fibrillization rates,
based on the premise that residue 87 is in the central
hydrophobic region, and substitutions or deletions in
this region have been shown to modulate aSyn self-
assembly [7, 47]. In contrast to our observation that
substitutions at position 87 had no impact on aSyn
neurotoxicity in primary midbrain cultures (Fig. 2),
A53T/S87N and h-aSyn Chimera S87N exhibited a
reduced fibrillization lag time compared to h-aSyn
A53T and h-aSyn Chimera, respectively (Figure S3A,
B). Moreover, m-aSyn N87S and m-aSyn Chimera/
N87S formed amyloid-like fibrils with a longer lag
time compared to m-aSyn and m-aSyn Chimera, re-
spectively (Figure S3C, D).
Collectively, these results suggest that differences in
neurotoxicity among the human, mouse, and chimeric
aSyn variants (Figs. 2, 3 and 4) correlate weakly with dif-
ferences in fibrillization rates.
Effects of human/mouse aSyn mismatches on fibril
morphology and dimensions
Next, we examined the impact of human/mouse aSyn
mismatches on fibril morphology and dimensions based
on evidence that different types of aSyn fibrils (e.g. cylin-
drical fibrils versus flatter ribbons) can trigger different
levels of neurotoxicity in cellular and animal models
[53]. Examination of incubated samples of human,
mouse, and chimeric aSyn by AFM revealed that all of
the variants formed straight, rigid, unbranched fibrils,
organized either as individual fibrils or in fibril bundles
(Fig. 6a-d). Two types of fibrils (‘twisted’ and ‘non-
twisted’) were detected in samples of m-aSyn and h-
aSyn-Chimera, whereas only non-twisted fibrils were ob-
served in samples of h-aSyn-A53T and m-aSyn-Chimera
under our experimental conditions. The heights of the
non-twisted fibrils ranged from ~ 8 to ~ 11 nm, whereas
the heights of the ‘valley’ and ‘peak’ regions of the
twisted fibrils ranged from ~ 7 to ~ 9 nm and ~ 11 to ~
12 nm, respectively. The average pitch of twisted fibrils
formed by m-aSyn and h-aSyn Chimera was 123 ± 5 nm
and 91 ± 8 nm, respectively (Fig. 6e,f).
Further analysis of the fibrils by TEM also revealed the
presence of straight, rigid, unbranched fibrils for all of the
variants (Fig. 6g-l). The fibrils had properties similar to
those described for previously reported aSyn amyloid-like
fibrils (e.g. diameter of ~ 10–15 nm; apparent winding of
two fibrils around each other via a helical twist) [26].
Fig. 5 M-aSyn forms amyloid-like fibrils with a shorter lag time compared to human and chimeric aSyn variants. The formation of amyloid-like
fibrils was monitored in solutions of monomeric h-aSyn WT, h-aSyn A53T, and m-aSyn (a), or h-aSyn A53T, h-aSyn Chimera, m-aSyn, and m-aSyn
Chimera (b) (35 μM of each). The protein solutions were incubated at 37 °C with constant agitation and analyzed at various times for thioflavin T
fluorescence. The graphs show the mean normalized fluorescence (determined from 3 independent experiments; 3 technical replicates per
experiment) plotted against the incubation time. The dotted lines above and below each solid line correspond to the mean signal ± SEM. See
also Figure S3
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Similar features were also observed for fibrils formed by
aSyn variants with the S87N or N87S substitution. There
were no striking differences in fibril morphology among
the different aSyn variants, except that individual fibrils
formed by h-aSyn-Chimera had a twisted appearance
similar to that observed for this variant by AFM (in con-
trast, twisted fibrils of m-aSyn were not observed by
TEM). It is unclear why different results were obtained for
m-aSyn and h-aSyn Chimera via AFM versus TEM, al-
though this discrepancy can potentially be explained by
the fact that (i) the variants formed two different types of
twisted fibrils, as implied by their different pitch values
(Fig. 6e,f), and (ii) different types of fibrils adsorb with
different efficiencies to substrates with different proper-
ties such as the hydrophilic mica and hydrophobic
carbon-coated grids used here for AFM and TEM,
respectively [54].
Overall, these data suggest that differences in the
morphologies of aSyn fibrils formed under the self-
assembly conditions used in this study could potentially
contribute to differences in neurotoxicity among the hu-
man, mouse, and chimeric aSyn variants (Figs. 2, 3 and 4).
Effects of human/mouse aSyn mismatches on membrane-
induced aSyn aggregation
Based on our earlier finding that lipid-induced self-
assembly plays a key role in aSyn neurotoxicity [16], we
hypothesized that human-to-mouse substitutions should
lead to a decrease in aSyn aggregation propensity at
membrane surfaces. Our rationale was that although
aSyn aggregation is primarily driven by the central
hydrophobic region [7, 11, 16], modifications to the C-
terminal domain have been shown to modulate aSyn
self-assembly [55] and aSyn-membrane interactions [56]
through effects on long-range interactions.
As a first step, we characterized the human, mouse,
and chimeric variants in terms of membrane affinities,
based on the premise that differences in affinity could
lead to differences in the variants’ propensity to
undergo membrane-induced aggregation [16]. Recom-
binant h-aSyn WT, h-aSyn A53T, h-aSyn Chimera,
m-aSyn, and m-aSyn Chimera in a monomeric state
were titrated with SUVs composed of egg PG and egg
PC (1:1 mol/mol). Analysis of the samples via far-UV
CD, a method used to monitor the increase in aSyn
α-helical structure that results from binding of the
protein to phospholipids, yielded similar lipid titration
curves, Kd values, and maximum α-helical contents
for all of the aSyn variants (Fig. 7a; Table S1). These
results suggested that the C-terminal human/mouse
mismatches have little effect on the affinity of aSyn
for phospholipid membranes, or on the degree of α-
helical structure adopted by the protein in the pres-
ence of saturating lipid.
Next, we compared the human, mouse, and
chimeric aSyn variants in terms of their ability to
undergo membrane-induced aggregation using a
lipid-flotation assay. The proteins were incubated
with PG:PC SUVs under conditions that promote
aSyn self-assembly, and the membrane fraction was
isolated by gradient centrifugation and analyzed via
Western blotting. The lane loaded with h-aSyn WT
contained immunoreactive bands at ~ 45 and 60
kDa, whereas the lane containing h-aSyn A53T or
m-aSyn Chimera displayed more extensive laddering,
including bands at 75 and 100 kDa, and an intense
smear of aSyn immunoreactivity in the region of the
gel above 245 kDa (Fig. 7b). In contrast, high
molecular-weight species were markedly less abun-
dant in the lanes loaded with h-aSyn Chimera or m-
aSyn. Densitometry analysis revealed a ~ 2-fold
greater ratio of total oligomer band intensity to
monomer band intensity in the h-aSyn A53T and
m-aSyn Chimera samples compared to the h-aSyn
Chimera and m-aSyn samples, respectively (Fig. 7b).
Although the results revealed a trend towards an in-
crease in the oligomer/monomer ratios for h-aSyn
A53T and m-aSyn Chimera compared to the human
WT protein, these effects did not reach statistical
significance. Collectively, these data suggested that
the human-to-mouse substitutions at positions 121
and 122 interfere with membrane-induced aSyn
aggregation.
Effects of human/mouse aSyn mismatches on a-Syn-
mediated membrane disruption
A number of groups have reported that aSyn aggregation
at the membrane can affect bilayer integrity via a mech-
anism involving phospholipid extraction coupled with
aggregate growth [19, 21]. Recently, we found that two
familial aSyn mutants with a high propensity to form
oligomers at membrane surfaces (A30P and G51D) [16]
efficiently triggered vesicle disruption under incubation
conditions suitable for membrane-induced aggregation,
whereas a variant with a low propensity to undergo self-
assembly at the membrane (A29E) exhibited no vesicle
permeabilization activity [22]. Thus, we hypothesized
that h-aSyn A53T and m-aSyn Chimera should elicit
greater membrane disruption than h-aSyn Chimera and
m-aSyn, based on the relative propensities of these vari-
ants to undergo membrane-induced aggregation (Fig.
7b). To examine this hypothesis, we compared the hu-
man, mouse, and chimeric aSyn variants in terms of
their ability to disrupt vesicles using a dye release assay.
PG-PC SUVs pre-loaded with the fluorescent dye calcein
at a concentration leading to self-quenching were incu-
bated with the aSyn variants in monomer form at 37 °C.
Membrane permeabilization was assessed by monitoring
Landeck et al. Molecular Neurodegeneration           (2020) 15:49 Page 14 of 23
Fig. 6 (See legend on next page.)
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the increase in fluorescence intensity resulting from
dequenching of the dye after its release from the vesicles
and dilution in the surrounding buffer. Upon extended
incubation, all of the aSyn-SUV mixtures displayed a
time-dependent increase in fluorescence, in contrast to
the control sample consisting of vesicles without protein
(Fig. 7c). After 120 h, the fluorescence emission observed
for h-aSyn A53T and m-aSyn Chimera (corresponding
to a yield of ~ 55% of the maximal signal obtained by
lysing the vesicles with detergent) was 2.5- and 1.5-fold
greater than that observed for h-aSyn Chimera and m-
aSyn, respectively (Fig. 7c). H-aSyn WT produced a
similar increase in fluorescence compared to h-aSyn
A53T and m-aSyn Chimera. Together, these data sug-
gested that the human-to-mouse substitutions at posi-
tions 121 and 122 interfere with aSyn-mediated vesicle
disruption under conditions compatible with aSyn aggre-
gation at the membrane surface.
Discussion
Understanding how human and mouse aSyn differ in
terms of pathobiology is a high priority in the synuclein-
opathy field not only because of the A/T mismatch at
position 53 relevant to familial PD, but also because of
the widespread use of genetically engineered mice to in-
vestigate molecular underpinnings of aSyn neuropathol-
ogy in vivo. Previously, it was reported that transgenic
mice expressing m-aSyn downstream of the Thy-1 pro-
moter show evidence at post-mortem examination of
extranigral aSyn accumulations similar to those observed
in mice expressing WT or mutant forms of h-aSyn [57],
but no evidence of a neurodegenerative phenotype in
contrast to mice expressing h-aSyn A53T or h-aSyn
A30P downstream of the same promoter [58]. Moreover,
Lashuel and colleagues [59] showed that endogenous m-
aSyn interferes with the formation of Lewy-like inclu-
sions by h-aSyn WT in cultured neurons and in mouse
brain. Here we report that m-aSyn has a reduced pro-
pensity to elicit dopaminergic cell death compared to h-
aSyn A53T in primary midbrain cultures and exhibits a
similar effect when expressed from an AAV vector in rat
SN. Furthermore, we show for the first time that this
differential toxicity is associated with differences in
aSyn-mediated vesicle disruption and aggregation at the
membrane surface, rather than differences in aSyn fibril-
lization previously suggested to be important for modu-
lating aSyn toxicity [60]. Most importantly, we provide
evidence that these characteristics of the overtly toxic h-
aSyn A53T variant can be blunted, down to the same
level of m-aSyn, by modification of only 2 amino acid
residues in positions 121 and 122 of the protein.
Our findings are consistent with the idea that m-aSyn
has a reduced propensity to elicit neurotoxicity com-
pared to h-aSyn A53T as a result of attenuation of the
toxic effects of threonine 53 in the mouse protein by
variations in other sites of the protein. Moreover, these
results support the hypothesis that mice show no signs
of neurodegeneration despite expressing an aSyn variant
with a threonine residue at position 53 at least in part
because m-aSyn is intrinsically less toxic than h-aSyn
A53T. The lack of nigral degeneration in mouse models
with altered expression of proteins that interact func-
tionally with aSyn, including transgenic mice over-
expressing LRRK2 [61] and DJ-1 knockout mice [62],
could also potentially be explained by the reduced
neurotoxicity of endogenous m-aSyn. Nevertheless, des-
pite its lower intrinsic toxicity, m-aSyn can also contrib-
ute to dopaminergic cell death in other models relevant
to nigral degeneration, including mice treated with
MPTP [63]. In addition to the intrinsic biochemical dif-
ferences between h-aSyn A53T and m-aSyn reported
here, other factors including differences in neurochem-
istry between the nigrostriatal systems of mice and
humans [64, 65] could also account at least in part for
the apparent absence of early-onset aSyn neuropathology
in mice in contrast to human A53T patients.
Our data are in line with previous results showing that
rat aSyn, identical to m-aSyn except for a single G-to-S
mismatch at position 121, triggers less extensive nigral
degeneration compared to h-aSyn WT, h-aSyn A30P, or
(See figure on previous page.)
Fig. 6 Human, mouse, and chimeric aSyn variants form amyloid-like fibrils with similar dimensions but different morphologies. (A-D) Results of
AFM analysis of fibrils prepared from recombinant h-aSyn A53T (a), m-aSyn (b), h-aSyn Chimera (c), and m-aSyn Chimera (d). Panels A(i) – D(i) on
the left show typical AFM topographic images of fibrils formed by each aSyn variant. Dashed boxes indicate areas shown at a higher
magnification in a spectral color scheme in panels A(ii) – D(ii). Panels A(iii)-D(iii) on the right show cross-section profiles. Regions of the fibrils
from which the profiles are taken are shown with white solid lines on the AFM images in panels A(ii)-D(ii). Twisted fibrils were observed for m-
aSyn (B) and h-aSyn Chimera (C). Twisted and non-twisted fibrils account for 65 and 35% (respectively) of total fibrils formed by m-aSyn, and 76
and 24% (respectively) of total fibrils formed by h-aSyn Chimera. Cross-section profiles in panels A(iii) and D(iii) reveal heights of non-twisted
fibrils (~ 8–11 nm). Cross-section profiles 1 and 2 reveal heights of twisted fibrils at valley regions (~ 7–9 nm) and peak regions (~ 11–12 nm),
respectively, in panels B(iii) and C(iii). (E, F) Histograms showing distances between peaks of twisted fibrils formed by m-aSyn (e) and h-aSyn
Chimera (f). The distances were determined from cross-section profiles obtained along the long axis of the fibrils. (G-L) Representative TEM
images of fibrils formed by h-aSyn WT (g), h-aSyn A53T (h), m-aSyn (i), h-aSyn Chimera (j), and m-aSyn Chimera (k). Scale bar, 100 nm. (l) Higher-
magnification images generated from boxed regions of panels G, I, and J show a pair of fibrils wound around each other via a helical twist (I),
two fibrils aligned in parallel (II), or individual fibrils with a twisted morphology (III and IV)
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Fig. 7 Human/mouse mismatches at positions 121 and 122 affect membrane-induced aSyn aggregation and aSyn-mediated vesicle disruption. a
Solutions of recombinant aSyn variants were incubated with increasing concentrations of SUVs composed of egg PG:PC (1:1 mol:mol) and
analyzed by far-UV CD to determine [θ]MR,222. The data were fit to eq. 3 (see ‘Experimental Procedures’), and values for Kd, minimum [θ]MR,222, and
maximum α-helical content were determined from the values of the fit parameters (Table S1). b Monomeric aSyn variants were incubated with
PG:PC SUVs (protein-to-lipid ratio, 1:20 mol/mol) at 37 °C for 72 h. Left: Representative Western blot image (the vertical line to the right of the
image shows the region of the blot with bands corresponding to oligomeric forms of aSyn). Right: Bar graph showing the ratio of total oligomer
band intensity to monomer band intensity determined for each sample. c Calcein-loaded SUVs were incubated in the absence (‘ctrl’) or presence
of aSyn variants. Calcein release was monitored via fluorescence measurements using excitation and emission wavelengths of 485 nm and 515
nm, respectively. Left: graph showing % dye release versus time, with 100% release determined as the signal obtained from vesicles treated with
Triton X-100. Right: table listing P values determined for vesicle permeabilization data obtained at the 120 h time point (a more complete listing
of P values at different time points is presented in Table S2). The data in (b) and (c) are presented as the mean ± SEM, n = 4 (B) or n = 3 (C). *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA (b) or two-way ANOVA (c) followed by Tukey’s multiple comparisons post hoc test
(a square root transformation was carried out on the data in panel c)
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h-aSyn A53T when expressed from a lentiviral vector in
rat midbrain [28]. Moreover, we observed that rat aSyn
has a similar blunted response of nigral dopaminergic
cell death compared to mouse aSyn in the rAAV-
mediated overexpression model in the rat [29]. Another
group reported evidence of TH+ neuron loss and an ac-
cumulation of Lewy-like inclusions in the SN of rats
injected intrastriatally with preformed fibrils (PFFs) pre-
pared from recombinant m-aSyn [66]. A similar but less
pronounced neuropathological phenotype was observed
upon injecting a sample of non-fibrillized m-aSyn in rat
midbrain, although the interpretation of the results was
complicated by uncertainty about the degree of aSyn
oligomerization in the injected, non-fibrillar protein
sample.
A key finding of this study was the observation in both
primary mesencephalic cultures and rat midbrain that (i)
h-aSyn Chimera, a variant of h-aSyn A53T with m-aSyn
residues introduced at positions 121 and 122, was less
neurotoxic than h-aSyn A53T; and (ii) m-aSyn Chimera,
a variant of m-aSyn with human aSyn residues intro-
duced at positions 121 and 122, was more neurotoxic
than the mouse protein. From these results, we infer that
the presence of glycine and serine residues at positions
121 and 122 of m-aSyn (respectively) is largely respon-
sible for offsetting the expected neurotoxic effects of
threonine 53 in the murine sequence. In turn, these
findings reveal for the first time that residues 121 and
122 play a key role in modulating aSyn-mediated neuro-
degeneration. Notably, in contrast to the striking effects
of human/mouse substitutions at positions 121 and 122,
the S87N or N87S substitution had no impact on the
ability of human, mouse, or chimeric aSyn variants to
trigger dopaminergic cell death in primary midbrain
cultures, suggesting that the variations in the two C-
terminal residues are unique in their impact on the tox-
icity. In support of these findings, a number of groups
have shown that modifications in the C-terminal do-
main, including truncation [47, 50] and Y125 phosphor-
ylation [48], affect aSyn neurotoxicity in cellular and
animal models.
Previously, m-aSyn was shown to form amyloid-like fi-
brils with a reduced lag time and a greater elongation
rate compared to h-aSyn WT or h-aSyn A53T [25, 26].
Here we confirmed these earlier findings and found that
two chimeric variants, h-aSyn Chimera and m-aSyn
Chimera, undergo less rapid fibrillization than the
mouse protein. These results indicate that the human-
to-mouse substitutions at positions 121 and 122 are ne-
cessary but not sufficient for the enhanced fibrillization
rate of m-aSyn relative to h-aSyn A53T. Because the
human-to-mouse and mouse-to-human substitutions at
positions 121 and 122 do not have opposite effects on
the rate of aSyn fibrillization, we infer that the impact of
each of these substitutions on aSyn self-assembly is
dependent on the sequence context, potentially because
residues 121 and 122 are involved in long-range intra-
molecular interactions that influence the rate of aSyn
self-assembly [8, 9]. Additional data revealed that vari-
ants of h-aSyn A53T and h-aSyn Chimera with the
S87N substitution form fibrils with a decreased lag time,
consistent with previously reported effects of this muta-
tion [25], whereas variants of m-aSyn and m-aSyn
Chimera with the N87S substitution form fibrils with an
increased lag time.
Importantly, however, differences in fibrillization rates
among the human, mouse, and chimeric aSyn variants
correlate only weakly with differences in neurotoxicity.
For example, h-aSyn A53T, h-aSyn Chimera, m-aSyn,
and m-aSyn Chimera exhibit the following order of
fibrillization rates:
m-aSyn ≥ m-aSyn Chimera > h-aSyn A53T > h-aSyn
Chimera.
In contrast, the same variants exhibit the following
order of neurotoxicity:
h-aSyn A53T ≈m-aSyn Chimera > m-aSyn ≈ h-aSyn
Chimera.
Moreover, despite causing changes in aSyn fibrilliza-
tion lag times, the S87N and N87S substitutions have no
impact on aSyn neurotoxicity in primary midbrain cul-
tures, further highlighting the weak correlation between
fibrillization propensity and aSyn-mediated neurodegen-
eration revealed by our study. The lack of a tight
correlation may reflect the fact that in mammalian cells
non-membrane-bound aSyn adopts a compact disor-
dered conformation that is apparently incompatible with
efficient fibrillization [5]. Thus, a perturbation that fa-
vors or hinders fibril formation by recombinant, natively
unfolded aSyn in solution may have a very different ef-
fect on the protein’s conversion to neurotoxic species in
its native intracellular environment.
AFM and TEM analyses revealed that human, mouse,
and chimeric aSyn formed amyloid-like fibrils with dif-
ferent morphologies under the experimental conditions
used here. Namely, m-aSyn and h-aSyn Chimera, the
two variants with reduced neurotoxicity, formed both
twisted and non-twisted fibrils, whereas only non-
twisted fibrils were formed by h-aSyn A53T and m-aSyn
Chimera. These results are consistent with solid-state
NMR data showing that fibrils formed by h-aSyn WT
and m-aSyn differ in terms of protofilament substructure
[67, 68], although previous EM analyses revealed no
major morphological differences between fibrils pre-
pared from human A53T and mouse aSyn [25, 69].
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Multiple groups have shown that injecting PFFs into the
brains of WT or transgenic rodents initiates the aggrega-
tion of endogenous aSyn via a seeding mechanism, lead-
ing to the formation of Lewy-like inclusions [66, 70, 71].
Moreover, evidence suggests that different types of fibrils
(e.g. cylindrical fibrils versus ribbons distinguishable by
EM) can act as prion-like ‘strains’ with different abilities
to undergo cell-to-cell transmission throughout the
brain [53]. Our AFM and TEM data imply that m-aSyn
and h-aSyn Chimera could potentially form different fi-
brillar strains (characterized by increased amounts of
twisted fibrils) compared to the other aSyn variants, and,
therefore, the differences in in vivo neurotoxicity re-
ported here could be due to differences in the variants’
abilities to seed aSyn neuropathology in rat brain. How-
ever, this interpretation is challenged by evidence that (i)
h-aSyn A53T can form twisted fibrils under certain incu-
bation conditions [72]; and (ii) PFFs formed from re-
combinant m-aSyn induce inclusion formation and
dopaminergic cell death with greater or similar efficiency
(respectively) compared to h-aSyn A53T PFFs following
their injection in mouse SN [73], in contrast to the re-
duced neurotoxicity of m-aSyn compared to h-aSyn
A53T reported here. Additional studies are needed to as-
sess whether human, mouse, or chimeric aSyn variants
produce different fibrillar strains with different levels of
neurotoxicity in vivo.
Previously we reported that two familial substitutions,
A30P and G51D, increase aSyn neurotoxicity by enhan-
cing the protein’s ability to form aggregates at mem-
brane surfaces [16]. Here we show that two aSyn
variants with a higher propensity to elicit dopaminergic
cell death in primary culture and in vivo, h-aSyn A53T
and m-aSyn Chimera, undergo membrane-induced self-
assembly with greater efficiency compared to two vari-
ants with lower neurotoxicity, h-aSyn Chimera and m-
aSyn. These results suggest that mouse-to-human substi-
tutions at positions 121 and 122 cause an increase in
aSyn neurotoxicity by promoting aSyn aggregation at
membrane surfaces, whereas human-to-mouse substitu-
tions have the opposite effect. Because all of the aSyn
variants examined in this study exhibited similar affin-
ities for PG:PC SUVs, we infer that human-to-mouse
substitutions interfere with lipid-induced aSyn aggrega-
tion not by favoring binding of the central hydrophobic
domain to the membrane, but rather by inducing a con-
formational change in the C-terminal region that
disrupts aSyn self-assembly, potentially via perturbation
of long-range interactions [8, 9, 56]. Consistent with this
scenario, data from several studies suggest that
modifications in the C-terminal region (namely, Y125
phosphorylation or nitration, or the nitration of all three
C-terminal tyrosine residues) can modulate the con-
formation of the N-terminal and central hydrophobic
domains of the membrane-bound form of the protein
[56, 74, 75]. These findings support the idea that long-
range interactions can occur in the membrane-
associated form of aSyn, in turn suggesting that the
human-to-mouse substitutions at positions 121 and 122
could potentially influence membrane-induced aSyn ag-
gregation by altering these intramolecular contacts.
Moreover, Burré et al. [76] have proposed a model
wherein oligomers formed by aSyn at the membrane
surface consist of neighboring aSyn molecules with their
C-terminal alpha-helices arranged in an anti-parallel
configuration. In this arrangement, the aspartate residue
at position 121 of human aSyn could potentially partici-
pate in electrostatic interactions with positively charged
residues on a neighboring subunit, and in turn these in-
teractions could favor the formation of pathological aSyn
aggregates at the membrane surface. This idea is also
supported by computational data from our group sug-
gesting that intermolecular interactions between the C-
terminal domain and central hydrophobic region play a
key role in aSyn dimerization at the surface of anionic
phospholipid membranes [77].
In the current study and in our earlier work [16, 22],
SDS-resistant aSyn oligomers were detected in the lipid
fraction of protein/SUV mixtures isolated by lipid
flotation. These data indicate that membrane-bound
aSyn oligomers were generated upon incubating the
protein with SUVs. The formation of these membrane-
bound oligomers could occur as a result of (i) aSyn
aggregation at the membrane surface, or (ii) aSyn aggre-
gation in solution, followed by the binding of the aggre-
gates to the membrane. Three observations argue
against the second scenario. First, we find that aSyn does
not form aggregates when incubated in the absence of
SUVs under the same conditions as those used in the
membrane-induced aggregation assay. Second, the rela-
tive rates at which aSyn variants form oligomers in the
presence of SUVs correlate poorly with the relative rates
at which the variants undergo self-assembly in the ab-
sence of phospholipids [16]. Third, we recently showed
that ENSA, a protein that interacts selectively with
membrane-bound aSyn [78], inhibits aSyn aggregation in
the presence of SUVs, whereas it does not interfere with
aSyn fibrillization in the absence of lipids [22]. The fact
that ENSA does not inhibit aSyn fibril formation in the
absence of SUVs suggests that the inhibitory effect of
ENSA on aSyn self-assembly in the presence of lipids
must arise from its interaction with aSyn at the mem-
brane surface. In turn, this evidence supports the idea
that aSyn forms oligomers on the membrane when incu-
bated with SUVs under the conditions described here.
Importantly, our data reveal a strong correlation be-
tween aggregation propensity at membrane surfaces
and neurotoxicity among the human, mouse, and
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chimeric aSyn variants, and thus they further support
the hypothesis that lipid-induced self-assembly plays a
key role in aSyn-mediated neurodegeneration [11, 16,
18, 22]. The importance of membrane-induced aSyn
aggregation to the pathogenesis of synucleinopathy
disorders is further underscored by evidence that
non-membrane-associated aSyn adopts a compact,
aggregation-resistant conformation, with little expos-
ure of the central hydrophobic region, in mammalian
cells [5]. Although it is uncertain why all of the aSyn
variants examined here formed PK-resistant aggre-
gates in rat striatum, one explanation could be that
the inclusions consist of fibrils derived from both
membrane-bound and non-membrane-bound forms of
aSyn [20, 21]. Accordingly, a decrease in the levels of
fibrils formed in the presence of lipids could be offset
by an increase in the levels of fibrils formed away
from the membrane in the case of m-aSyn, whereas
the opposite scenario could be true in the case of h-
aSyn A53T. Consistent with this idea, data reported
by multiple groups imply that aSyn can undergo vari-
ous forms of self-assembly, leading to the formation
of different types of aggregated species with different
degrees of neurotoxicity, in cell culture models, aSyn
transgenic mice, and the brains of synucleinopathy
patients [79–83]. Although our results highlight the
importance of membrane-induced aSyn aggregation in
aSyn-mediated dopaminergic cell death, we suggest
that aSyn aggregates formed both at membrane sur-
faces and in solution likely contribute to the overall
neuropathology of synucleinopathy disorders. Asses-
sing whether differences in the rates or extents of
aSyn oligomerization in the absence of membranes
also account at least in part for differences in neuro-
toxicity among the aSyn variants is an important goal
for future studies.
A final key outcome of this study was our finding that
the relatively neurotoxic variants h-aSyn A53T and m-
aSyn Chimera elicit the disruption of synthetic vesicles
under conditions favoring membrane-induced aSyn ag-
gregation with greater efficiency than the less toxic vari-
ants h-aSyn Chimera and m-aSyn. These data suggest
that mouse-to-human substitutions at positions 121 and
122 enhance aSyn neurotoxicity by promoting aSyn-
mediated membrane permeabilization, whereas human-
to-mouse substitutions have the opposite effect. Unex-
pectedly, we found that h-aSyn WT triggered vesicle dis-
ruption to a similar extent as h-aSyn A53T and m-aSyn
Chimera. This observation was inconsistent with the fact
that h-aSyn WT exhibited a non-significant trend to-
wards less extensive membrane-induced self-assembly,
or with evidence from our earlier studies that h-aSyn
WT is considerably less toxic than h-aSyn A53T in pri-
mary midbrain cultures [16] and causes neurodegeneration
less rapidly than h-aSyn A53T in rat midbrain [84]. As one
possibility, the current findings can be interpreted to mean
that h-aSyn WT engages in different molecular interac-
tions during aggregation at the membrane surface com-
pared to h-aSyn A53T or m-aSyn Chimera, resulting in an
increase in the extent of membrane permeabilization rela-
tive to the total amount of aggregate formed. Consistent
with this idea, evidence from multiple studies suggests that
h-aSyn WT and familial aSyn mutants can form different
types of amyloid-like fibrils [85–87]. Overall, our data re-
veal a strong correlation between vesicle disruption and
neurotoxicity among the human, mouse, and chimeric
aSyn variants, and thus they support the notion that mem-
brane permeabilization associated with lipid-induced self-
assembly plays a key role in aSyn-mediated neurodegener-
ation. These findings are consistent with evidence that h-
aSyn E57K, a variant with a high propensity to form aggre-
gates on a supported lipid bilayer and elicit membrane
damage, causes extensive dopaminergic cell death when
expressed in rat SN [19, 51].
Previous findings reported by Volles et al. [88, 89] sug-
gest that aSyn oligomers formed in the absence of mem-
branes fail to permeabilize low-diameter vesicles
composed of a mixture of anionic and zwitterionic lipids.
Accordingly, we infer that the vesicle disruption ob-
served in aSyn-SUV mixtures in this study and in our
earlier work [22] results from aSyn self-assembly at the
membrane surface. These observations further corrobor-
ate the idea that aSyn forms oligomers on the membrane
when incubated with SUVs under the conditions de-
scribed in this study. Moreover, oligomeric m-aSyn pre-
pared in the absence of membranes was reported by
Volles et al. [88] to permeabilize vesicles composed of
anionic lipids with a similar efficiency compared to olig-
omeric h-aSyn A53T, contrary to the difference in the
variants’ neurotoxicity reported here. This observation
suggests that vesicle disruption associated with lipid-
induced aSyn aggregation plays a more important role
than membrane permeabilization by preformed oligo-
mers in aSyn-mediated neurodegeneration in vivo.
Conclusions
We report for the first time that m-aSyn has a reduced abil-
ity to elicit dopaminergic cell death compared to h-aSyn
A53T in primary mesencephalic cultures and in rat mid-
brain. Our results highlight the central importance of
membrane-induced aSyn aggregation and vesicle disruption
in aSyn neurotoxicity, and they reveal a C-terminal se-
quence motif encompassing residues 121 and 122 with an
important role in modulating these activities. Collectively,
these findings provide a strong rationale for developing
therapies aimed at inhibiting aSyn aggregation at mem-
brane surfaces, including interventions that target the C-
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terminal domain, as a strategy to slow neurodegeneration
in the brains of synucleinopathy patients [16, 18, 22].
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